PTC Therapeutics exec. VP Boulding sells $827,232 in stock

Mark Elliott Boulding, the Executive Vice President and Chief Legal Officer of PTC (NASDAQ:PTC) Therapeutics, Inc. (NASDAQ:PTCT), a $4.3 billion market cap biotech company, recently executed a series of stock transactions involving the company’s common stock. According to a recent SEC filing, Boulding sold shares totaling $827,232. The transactions, which took place on March 12, 2025, involved sales at prices ranging from $53.23 to $53.31 per share, near the stock’s 52-week high of $55.60 after surging over 55% in the past six months.

In addition to the sales, Boulding also exercised stock options to acquire shares at $33.02 each, with a total value of $512,503. Following these transactions, Boulding holds 103,901 shares of PTC Therapeutics directly. These transactions were conducted under a pre-established Rule 10b5-1 trading plan. According to InvestingPro analysis, the company appears slightly overvalued at current levels, with additional insights available in the comprehensive Pro Research Report covering this and 1,400+ other US stocks.

In other recent news, PTC Therapeutics reported its Q4 2024 earnings, revealing a slight miss in earnings per share (EPS) but meeting revenue expectations. The company posted an EPS of -$0.85, compared to the forecasted -$0.79, while revenue came in at $213 million, closely aligning with the anticipated $213.45 million. For the full year 2024, PTC Therapeutics achieved revenue of $877 million, surpassing its guidance. BofA Securities upgraded PTC Therapeutics’ stock from Underperform to Neutral, raising the price target to $55, following the FDA’s expedited review of vatiquinone, an investigational drug for Friedreich’s ataxia. Meanwhile, Scotiabank (TSX:BNS) initiated coverage on PTC Therapeutics with a Sector Perform rating and a $55 price target, indicating the stock is fairly valued. Cantor Fitzgerald maintained its Overweight rating with a price target of $113, reflecting confidence in the company’s potential despite slightly lowered revenue projections for 2025. These developments highlight the company’s strong financial position and its strategic efforts in advancing its drug pipeline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.